EFFECT OF NEW ANDROGEN RECEPTOR AXIS-TARGETED AGENTS ON SURVIVAL OF CASTRATION-RESISTANT PROSTATE CANCER-Reference-Cited by-同舟云学术

EFFECT OF NEW ANDROGEN RECEPTOR AXIS-TARGETED AGENTS ON SURVIVAL OF CASTRATION-RESISTANT PROSTATE CANCER

Published:2021-10-20 Issue:4 Volume:112 Page:207-214
ISSN:0021-5287
Container-title:The Japanese Journal of Urology
language:en
Short-container-title:Jpn. j. urol

Author:

Shimabukuro Tomoyuki¹,Ohmi Chietaka¹,Nagamitsu Ryoko¹,Shiraishi Koji²

Affiliation:

1. Department of Urology, Ube-kosan Central Hospital Corp

2. Department of Urology, Graduate School of Medicine, Yamaguchi University

Publisher

Japanese Urological Association

Subject

Urology

Link

https://www.jstage.jst.go.jp/article/jpnjurol/112/4/112_207/_pdf

Reference22 articles.

1. 1) Huggins C and Hodges CV: Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res, 1, 293-297, 1941.

2. 2) Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S and Hirao Y: Combined androgen blockade with bicalutamide for advanced prostate cancer. Long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer, 115(15), 3437-3445, 2009.

3. 3) Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A and Hussain M: Design and endpoints of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group. J. Clin. Oncol., 26, 1148-1159, 2008.

4. 4) Nelson WG, De Marzo AM and Isaacs WB: Prostate cancer. N. Engl. J. Med., 349, 366-381, 2003.

5. 5) Sartor O and de Bono JS: Metastatic prostate cancer. N. Engl. J. Med., 378, 645-657, 2018.